Nowadays, standard systemic treatment for advanced non oncogene-addicted NSCLC is represented by the combination of chemotherapy and ICIs, which shown to be effective in all subgroups of patients regardless of programmed death-ligand 1 (PD-L1) expression, with the larger benefit being revealed when PD-L1 expression is upper than 50% [7, 8]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.